
Product Data Sheet

Product Name: GENZ-882706 (RA03546849)

Cat. No.: GC31842

Chemical Properties

Cas. No. 2070864-35-4

SMILES COC1=CC=C([C@@H]2OC(C=CC(CN3C4=NC=C(C#CC(N)(C)C)C=C4N=C3)=C5)=C5OC2)C=N1Formula C₂₆H₂₅N₅O₃ M.Wt 455.51

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Cell experiment:**

To determine the effect of GENZ-882706 on the proliferation of primary murine microglial cells following LPS or CSF-1 stimulation, GENZ-882706 (500 nM) is added to appropriate assay wells. 25 µL medium are also added to all cells only wells at this time. 25 µL of LPS at 10 ng/mL or 100 ng/mL or CSF-1 at 100 ng/mL are then added to appropriate wells. 25 µL of medium are added to wells not receiving LPS or CSF-1 to bring the final volume of all assay wells to 150µL[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal experiment:

Mice[1]Mycobacterium tuberculosis is induced in a secondary progressive experimental autoimmune encephalomyelitis (EAE) model in NOD mice with an emulsion of MOG 35-55 and CFA. Therapeutic treatment with Genz-882706 (25mg/kg/day) or vehicle control is started on Day 27 post-disease induction when mice began to enter the progressive stage of disease. Inflammatory/neurotoxic mediators in the CNS are measured through protein analysis in homogenate and gene expression[1].

References:

[1]. Kane, et al.
Colony
Stimulating
Factor-1
Receptor (CSF-
1R) Inhibitors.
WO
2017015267A1

Background

GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.

Genz-882706 induces an increased level of proliferative activity on unstimulated cells 48 hours post treatment and the reason for this effect is unclear[1].

Daily treatment with Genz-882706 significantly reduces experimental autoimmune encephalomyelitis. Treatment with Genz-882706 in experimental autoimmune encephalomyelitis (EAE) mice results in significant decreases in MCP-1, IL-6, IL-1 β and IP-10 levels in spinal cord homogenates when compared to Vehicle treated animals. Treatment with Genz-882706 shows a significant increase in TNF- α levels in the spinal cord when compared to the vehicle treated group. Genz-882706 at both the 30 mg/kg

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

and the 100 mg/kg dose significantly reduces the number of microglia and monocytes/macrophages in the brain and spinal cord compared to the vehicle and LPS controls. Treatment with Genz-882706 modestly reduces CD80 expression on monocytes/macrophages in the brain[1].

[1]. Kane, et al. Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitors. WO 2017015267A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA